Assessing the Efficacy of Novel Anticoagulant in Atrial Fibrillation
Clinical studies require meticulous planning, with multiple endpoints used to assess a drug’s potential benefits and side effects. The increasing complexity has led to collaboration with Contract Research Organizations (CROs), providing specialized support in various phases of drug development. The U.S. CRO market shows steady growth, driven by the demand for expertise.
KEY FACTS:
- Objective: This randomized controlled trial evaluates the effectiveness and safety of a newly developed anticoagulant in preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation. The study aims to compare the new anticoagulant with standard-of-care anticoagulation therapy.
- Eligibility Criteria: Adults diagnosed with non-valvular atrial fibrillation and at moderate to high risk of stroke may be eligible to participate.
- Location: Cardiology departments of participating hospitals worldwide.
Previous Studies:
Clinical studies require meticulous planning, with multiple endpoints used to assess a drug’s potential benefits and side effects. The increasing complexity has led to collaboration with Contract Research Organizations (CROs), providing specialized support in various phases of drug development. The U.S. CRO market shows steady growth, driven by the demand for expertise.
- 2022 ITERUM THERAPEUTICS: SULOPENEM 500MG FOR UUTI
- 2022 REHALER: REBREATHING DEVICE FOR MIGRANE W/AURA
- 2022 FRACTYL: REVITA T2 DIABETES PIVOTAL STUDY
- 2022 NOVARTIS:INCLISIRAN SODIUM 300MG SC D1/M3
- 2022 NOVARTIS: INCLISIRAN ON MACE FOR CVD
- 2022 SENSE BIODETECTION: VEROS FOR COVID-19 DIAGNOSTIC
- 2022 CLINCOR: CIN-107 TO UNCONTROLLED HTN & CHRONIC KIDNEY DISEASE
Principal Investigator
- 2015 NOVONORDISK: 3995 TYPE1 DIABETICINSULINTRIAL
- 2014 SHIONOGI: 9232 NALDEMEDINETOOIC
- 2013GENKYOTEXGKT137831 TOTYPE2 DIABETES& ALBUMINURIA
- 2013 FERRIN: 000070 LUTREPULSEOMNIPOD
- 2013 ASTRAZENECA: MEDI-563 BENRALIZUMABTO
- 2023 GILEAD: GS-5245 NON-HOSPITALIZED WITH COVID-19
- 2023 BOEHRINGER INGELHEIM: BI 456906 4.8&6.0MG TO CVD/CKD
- 2023 ASTRAZENECA: AZD48315 5MG TO 1ST COPD
- 2023 ASTRAZENECA: AZD4831 2.5/5MG QD PO
- 2023 ELI LILLY: (CWM)/T2DM PROGRAM
- 2023 MERCK SHARP & DOHME: V116 0.5MLIM FOR PNEUMOCOCCAL DISEASE
- 2022 MODERNA: PHASE 1 MRNA VACCINE FOR HEALTHY 18-15Y/O
- 2022 ITERUM THERAPEUTICS: SULOPENEM 500MG FOR UUTI
- 2022 REHALER: REBREATHING DEVICE FOR MIGRANE W/AURA
- 2022 FRACTYL: REVITA T2 DIABETES PIVOTAL STUDY
- 2022 NOVARTIS:INCLISIRAN SODIUM 300MG SC D1/M3
- 2022 NOVARTIS: INCLISIRAN ON MACE FOR CVD
- 2022 SENSE BIODETECTION: VEROS FOR COVID-19 DIAGNOSTIC
- 2022 CLINCOR: CIN-107 TO UNCONTROLLED HTN & CHRONIC KIDNEY DISEASE
Be The First One To Know About New Upcoming Studies.
If you’re ready to take your knowledge to the next level and be ahead of the curve, join us today. Be the first one to know about new upcoming studies and embark on a journey of continuous learning, growth, and exploration. Your future of discovery starts here.
